Isoflavonoid compounds and methods for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-2023372287-A1
Application number	US-202318363328-A
Country	US
Kind code	A1
Filing date	Aug 1, 2023
Priority date	Nov 1, 2010
Publication date	Nov 23, 2023
Grant date	—

First claim

What is claimed is:

1 . A pharmaceutical composition comprising a compound of formula II or a pharmaceutically acceptable salt thereof:

wherein
R 1 is hydroxy, alkoxy, haloalkyl, or halo;
R 2 is hydroxy or alkoxy;
R 3 is alkyl, halo, or haloalkyl;
R 4 , R 5 , and R 6 are independently hydrogen, hydroxy, alkoxy, halo, haloalkyl, or alkyl; and
R 7 is alkyl or hydrogen.

2 . The composition of claim 1 , wherein R 1 is hydroxy or methoxy.

3 . The composition of any of claims 1 - 2 , wherein R 2 is hydroxy.

4 . The composition of any of claims 1 - 3 , wherein R 3 is methyl.

5 . The composition of any of claims 1 - 4 , wherein R 7 is methyl.

6 . A pharmaceutical composition comprising a compound of formula IV or a pharmaceutically acceptable salt thereof:

wherein
R 8 is hydrogen.

7 . The composition of any of claims 1 - 6 , wherein the composition further comprises an anti-cancer agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, epirubicin, cyclophosphamide, capecitabine, 5-fluorouracil, vinorelbine, trastuzumab or bevacizumab.

8 . The composition of any of claims 1 - 7 , wherein the composition further comprises a cyclodextrin.

9 . A kit comprising a composition of any of claims 1 - 8 and a sealable, plastic infusion bag.

10 . The composition of any one of claims 1 - 8 for use in inducing apoptosis in a cancer cell.

11 . The composition of any one of claims 1 - 8 for use in the treatment of cancer in an individual in need of cancer therapy.

12 . The composition of any one of claims 1 - 8 for use in increasing, inducing, or restoring sensitivity of a cancer cell to a chemotherapeutic agent, anti-cancer agent or radiation therapy.

13 . The composition of claim 12 , wherein the cancer cell has lost sensitivity to a chemotherapeutic agent, anti-cancer agent or radiation therapy.

14 . The composition of any one of claims 10 - 13 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer and cancers of the brain.

15 . The compound of any one of claims 10 - 14 , wherein said cancer is human breast cancer or ovarian cancer.

Assignees

• Mei Pharma Inc

Inventors

• Jeoffreys George
• Johnson Alison
• Heaton Andrew
• Moreno Ofir

Classifications

• A61K31/353 Primary

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K47/40

  Cyclodextrins; Derivatives thereof · CPC title